Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment

被引：0
|
作者：
L Bennett
Z Zhao
B Barber
X Zhou
M Peeters
J Zhang
F Xu
J Wiezorek
J-Y Douillard
机构：
[1] RTI Health Solutions,Department of Oncology
[2] Amgen Inc.,Department of Medical Oncology
[3] One Amgen Center Drive,undefined
[4] University Hospital Antwerp,undefined
[5] Centre René Gauducheau,undefined
[6] Boulevard J Monod,undefined
来源：
British Journal of Cancer | 2011年 / 105卷
关键词：
colorectal cancer; panitumumab; quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1495 / 1502
页数：7
相关论文
共 50 条
  • [21] Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC)
    Goldstein, Daniel A.
    Chen, Qiushi
    Howard, David H.
    Lipscomb, Joseph
    Ayer, Turgay
    El-Rayes, Bassel F.
    Flowers, Christopher
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] The Relationship Between Health-Related Quality of Life and Survival in Metastatic Colorectal Cancer Patients Treated With Korean Medicine
    Park, Sora
    Eo, Wankyu
    Lee, Sookyung
    [J]. INTEGRATIVE CANCER THERAPIES, 2018, 17 (01) : 65 - 72
  • [23] Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer
    Liang, Hong-Liang
    Hu, Ai-Ping
    Li, Sen-Lin
    Liu, Ji-Yong
    [J]. MEDICAL ONCOLOGY, 2014, 31 (06)
  • [24] Final results from PRECEPT: efficacy and safety of second-line treatment with panitumumab and FOLFIRI in patients with metastatic colorectal cancer (mCRC)
    Cohn, A.
    Smith, D. A.
    Neubauer, M. A.
    Richards, D.
    Watkins, D. L.
    Zhang, K.
    Yassine, M.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 347 - 347
  • [25] Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer
    Hong-Liang Liang
    Ai-Ping Hu
    Sen-Lin Li
    Ji-Yong Liu
    [J]. Medical Oncology, 2014, 31
  • [26] Combination treatment with aromatase inhibitor and capecitabine as first- or second-line treatment in metastatic breast cancer.
    Alvarado Miranda, Alberto
    Limon, Jesus
    Lara Medina, Fernando
    Arce, Claudia
    Wolfgang Zinser, Juan
    Bargallo Rocha, Enrique
    Mayte Villarreal-Garza, Cynthia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Evaluation of safety of bevacizumab as second-line treatment of patients with metastatic colorectal cancer
    Todorovic, Vladimir
    Saric, Nada Cicmil
    Lakicevic, Jadranka
    Sorat, Milan
    [J]. JOURNAL OF BUON, 2017, 22 (05): : 1131 - 1136
  • [28] Impact of fluoropyrimidine switching in sequential treatment of first- and second-line n unresectable colorectal cancer
    Nagata, Yusuke
    Sawada, Ryoichi
    Harada, Kentaro
    Mikuni, Hayato
    Ishikawa, Masashi
    Kano, Tomohiro
    Ishimoto, Utako
    Nishimura, Takashi
    Noguchi, Masaaki
    Ohkuma, Masahisa
    Nagasaki, Eijiro
    Amano, Katsushi
    Eto, Ken
    Yanaga, Katsuhiko
    Saruta, Masayuki
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 118 - 118
  • [29] Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy
    Heba Maged Ayoub
    Maha Lotfy Zamzam
    Eman Essam Elsemary
    Ihab Mohamed Hassanin
    Fifi Mostafa Elsayed
    [J]. BMC Cancer, 23 (1)
  • [30] Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy
    Ayoub, Heba Maged
    Zamzam, Maha Lotfy
    Elsemary, Eman Essam
    Hassanin, Ihab Mohamed
    Elsayed, Fifi Mostafa
    [J]. BMC CANCER, 2023, 23 (01)
12345